Neutralization capacity of antibodies elicited through homologous or heterologous infection or vaccination against SARS-CoV-2 VOCsSARS-CoV-2 VOCs에 대한 동종 또는 이종 감염 또는 백신 접종을 통해 유도된 항체의 중화 능력Article Published on 2022-07-042022-09-11 Journal: Nature Communications [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료기술, [키워드] Alpha antibody antigenic B.1 Beta Blood blood specimens Breakthrough infection breakthrough infections Clusters Combination Combined complex convalescent individual convalescent individuals Delta determined by elicited escape Gamma homologous homologous or heterologous Immune escape Immunity Infection isolates Last lead less neutralization Neutralization assay neutralization titer Neutralizing neutralizing capacity omicron Patient population immunity question raise SARS-CoV-2 SARS-CoV-2 isolate SARS-CoV-2 variant SARS-CoV-2 variants sera Seven specimen vaccinated individual vaccinated individuals vaccination Vaccinations variant variants VoC Zeta [DOI] 10.1038/s41467-022-31556-1 PMC 바로가기 [Article Type] Article
SARS-CoV-2, SARS-CoV, and MERS-CoV encode circular RNAs of spliceosome-independent originSARS-CoV-2, SARS-CoV 및 MERS-CoV는 spliceosome-independent origin의 원형 RNA를 인코딩합니다.Article Published on 2022-07-012022-09-11 Journal: Journal of medical virology [Category] Coronavirus, COVID19(2023년), SARS, 유전자 메커니즘, 치료기술, 치료제, [키워드] abundance acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 amplified Analysis approaches assays Autoimmune disease Autoimmune diseases Betacoronavirus betacoronaviruses breakpoint canonical Chain Reaction characterized Circular circular RNA complementary coronavirus Critical cytoplasmic demonstrated distribution Features Fluorescence highlight homologous Host In situ hybridization infected Vero E6 cells junction mechanism MERS-CoV Middle East Middle East respiratory syndrome Coronavirus N gene not limited offer polymerase chain polymerase chain reaction predicted probe respiratory syndrome coronavirus RNA RNA Biology RNA genome RNA genomes RNA sample RNA samples RNA synthesis RNase SARS-CoV SARS-CoV-2 sequenced severe acute respiratory syndrome Coronavirus transcriptional regulatory sequences Transcriptome Vero E6 VERO E6 cells viral pathogenesis viral transcriptome Virology [DOI] 10.1002/jmv.27734 PMC 바로가기 [Article Type] Article
Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients in a randomized phase 2 trial무작위 2상 시험에서 BBIBP-CorV 수용자에서 하이브리드형 백신 부스터의 안전성 및 면역원성Clinical Trial Published on 2022-06-272022-09-11 Journal: Nature Communications [Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단, 치료기술, 치료법, [키워드] 1:1 Administered Adverse reaction Adverse reactions age Antigen antigens BBIBP-CorV boost booster booster dose conducted dose double-blind elicited evaluate GMT greater group healthy Heterologous homologous IgG antibodies IgG antibody immunogenic immunogenicity incidence Neutralizing and IgG antibodies neutralizing antibody omicron Omicron variant participant Phase 2 phase 2 trial Randomized receive recipient recombinant COVID-19 vaccine regimens Safe Safety safety profile SARS-CoV-2 SARS-CoV-2 strain significantly higher three groups United Arab Emirate United Arab Emirates Vaccine variant variants of concern VOCs [DOI] 10.1038/s41467-022-31379-0 PMC 바로가기 [Article Type] Clinical Trial
A modified vaccinia Ankara vaccine expressing spike and nucleocapsid protects rhesus macaques against SARS-CoV-2 Delta infection스파이크와 뉴클레오캡시드를 발현하는 변형된 백시니아 앙카라 백신은 SARS-CoV-2 Delta 감염으로부터 붉은털 원숭이를 보호합니다Article Published on 2022-06-242022-09-11 Journal: Science Immunology [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료법, [키워드] added Beta Beta variant binding Blood CD4 CD8 T cell correlated cross-reactive cross-reactive antibody Delta delta variant Efficacy elicited expressed expressing FCS function furin furin cleavage site Heterologous homologous human ACE2 humoral IgG inactivated inactivation induce Infection intramuscular less lung mice moderate neutralized Neutralizing Neutralizing antibodies neutralizing antibody non-neutralizing antibody nose nucleocapsid positively correlated PROTECT rectum response rhesus macaque rhesus macaques robust SARS-CoV-2 SARS-CoV-2 vaccines secretion serum spike spike-specific IgG T cell T cell response T cell responses tested the SARS-CoV-2 vaccination Vaccine variant variants of concern virus VoC VOCs [DOI] 10.1126/sciimmunol.abo0226 PMC 바로가기 [Article Type] Article
Comparison of IgA, IgG, and Neutralizing Antibody Responses Following Immunization With Moderna, BioNTech, AstraZeneca, Sputnik-V, Johnson and Johnson, and Sinopharm’s COVID-19 VaccinesModerna, BioNTech, AstraZeneca, Sputnik-V, Johnson and Johnson 및 Sinopharm의 COVID-19 백신을 사용한 면역 후 IgA, IgG 및 중화 항체 반응의 비교Article Published on 2022-06-212022-09-12 Journal: Frontiers in Immunology [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] age Analysis analyzed antibody Antibody titers AstraZeneca automated binding blood sample categories category Combination comparable Correlation analysis COVID-19 COVID-19 vaccines demonstrated DNA dose doses effective ELISA expression group groups Heterologous highest homologous IgA IgG immunogenic investigated lowest moderate Moderna mRNA vaccine negative correlation neutralization Neutralizing Neutralizing antibodies neutralizing antibody Older reactogenicity response sandwich ELISA SARS-CoV-2 sera significant increase significantly higher Sinopharm Spearman specific neutralizing antibody statistically Trial vaccination Vaccination strategy Vaccine vaccinee vaccinees vectored vaccine virus Virus neutralization Virus-specific IgG Volunteer [DOI] 10.3389/fimmu.2022.917905 PMC 바로가기 [Article Type] Article
Virus-Like Particles Are Efficient Tools for Boosting mRNA-Induced Antibodies바이러스 유사 입자는 mRNA 유도 항체를 강화하기 위한 효율적인 도구입니다Article Published on 2022-06-162022-09-11 Journal: Frontiers in Immunology [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] antibodies Antibody Response Antibody responses approved boost COVID-19 economics Efficacy efficient Heterologous heterologous prime-boost heterologous prime-boost vaccination strategies homologous investigated maintain mRNA mRNA-1273 mRNA-1273 vaccine overcome Particle priming reduced regimen SARS-CoV-2 SARS-CoV-2 pandemic SARS-CoV-2 variant the antibody response Vaccination strategy Vaccine vaccine candidate Virus-like particle virus-like particles VLP VLPs VOCs were used [DOI] 10.3389/fimmu.2022.864718 PMC 바로가기 [Article Type] Article
Evaluation of the safety and immunogenicity of different COVID-19 vaccine combinations in healthy individuals: study protocol for a randomized, subject-blinded, controlled phase 3 trial [PRIBIVAC]건강한 개인에서 다양한 COVID-19 백신 조합의 안전성 및 면역원성 평가: 무작위, 피험자 맹검, 대조 3상 시험을 위한 연구 프로토콜 [PRIBIVAC]Article Published on 2022-06-162022-09-11 Journal: Trials [Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단, [키워드] adverse event adverse events anti-SARS-CoV-2 antibodies antibody approval best blood sample Blood samples BNT162b2 boost booster booster dose booster vaccinations cellular Cellular immune response collected Combination Comprehensive control arm Controlled clinical trial CoronaVac country COVID-19 COVID-19 vaccination COVID-19 vaccine COVID-19 vaccines demonstration different time point different time points dose Effectiveness Eligible participants Endpoint enrolment evade excluded group healthy Heterologous homologous host immunity humoral immune immune profiling immune response Immunity Immunocompromised immunogenicity Immunoglobulin immunoglobulins Inactivated vaccine Infection Intervention intervention arm Laboratory test Laboratory tests Local maintain mRNA mRNA vaccine mRNA-1273 omicron over parameters participant performed persistence phase Phase 3 phase 3 trial physical population immunity pregnant primary endpoint Probability quantity raising randomization Randomized Randomized controlled trial regimen Regulatory SARS-CoV-2 SARS-COV-2 infection Serious Adverse Event Serious Adverse Events Singapore Study protocol vaccination Vaccine vaccine availability vaccine booster vaccine candidate variants variants of concern volunteers wildtype [DOI] 10.1186/s13063-022-06345-2 PMC 바로가기 [Article Type] Article
Serological study of CoronaVac vaccine and booster doses in Chile: immunogenicity and persistence of anti-SARS-CoV-2 spike antibodies칠레의 코로나백 백신 및 부스터 용량에 대한 혈청학적 연구: 항-SARS-CoV-2 스파이크 항체의 면역원성과 지속성Article Published on 2022-06-092022-09-12 Journal: BMC Medicine [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] activating affected age anti-SARS-CoV-2 antibodies antibody antibody production Antibody Response Antibody titer BNT162b2 BNT162b2 vaccine booster booster dose ChAdOx1 ChAdOx1 vaccines collected Combination CoronaVac country Course COVID-19 COVID19 Decline dose elicited ELISA assay generate Heterologous homologous homologous or heterologous humoral Humoral response immunological Immunological memory implementation individual induce interquartile range IQR less magnitude median median age outbreak persistence Prevent remained response SARS-CoV-2 Spike protein the antibody response the disease the SARS-CoV-2 vaccinate vaccination vaccination schedule Vaccine [DOI] 10.1186/s12916-022-02406-0 PMC 바로가기 [Article Type] Article
Association of neutralizing breadth against SARS-CoV-2 with inoculation orders of heterologous prime-boost vaccinesClinical and Translational Report Published on 2022-06-092022-10-04 Journal: Med (New York, N.Y.) [Category] COVID19(2023년), MERS, SARS, 변종, 유전자 메커니즘, [키워드] Abstract Affect Analysis Animal experiment antibody antibody cross-reactivity antibody response against association B.1.617.2 Booster vaccine breadth China circulating clinical evidence clinical observation Cohort Commission conducted confounders Context cost-efficient strategy COVID-19 vaccination COVID-19 vaccine Department development elicit Evidence finding foundation funding Health care worker healthcare worker Heterologous heterologous prime-boost heterologous vaccination heterologous vaccine homologous homologous or heterologous immune responses immunological analysis inactivated Influenza Innovation International Laboratory test mechanism Multivariable regression natural Neutralization antibody neutralization titer Neutralizing Neutralizing activity physician PNA Program protective immunity Pseudovirus neutralization assay recipient SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants Science Serum Neutralization Shenzhen shown significantly lower subsequent suggested technology the United State the vaccine vaccination vaccination schedule Vaccine Vaccines variant variants veteran Virus neutralization Wuhan-Hu-1 [DOI] 10.1016/j.medj.2022.05.003 PMC 바로가기 [Article Type] Clinical and Translational Report
Immunological investigation of a multiepitope peptide vaccine candidate based on main proteins of SARS-CoV-2 pathogenSARS-CoV-2 병원체의 주요 단백질에 기반한 다중 에피토프 펩타이드 백신 후보의 면역학적 조사Article Published on 2022-06-092022-09-11 Journal: PLoS ONE [Category] COVID19(2023년), SARS, 변종, 치료법, [키워드] antigenic Cell complex cytotoxic T lymphocyte develop DNA E. coli Epitopes eukaryotic evaluated expression expression vectors granzyme granzyme B groups helper T lymphocyte Heterologous homologous IFN-γ IgG IgG2a IL-15 IL-21 IL-6 immune response immune responses Immunity immunized in silico in vitro in vivo indicated induce linear B linear B lymphocyte lymphocyte mammalian cell membrane protein mice multiepitope peptide vaccine multiepitope vaccine Multiepitope vaccines nucleocapsid Nucleocapsid phosphoprotein pathogen Pathogens pcDNA3.1 Penetrating peptide produced Protein regimen regimens SARS-CoV-2 SARS-COV-2 infection secretion significantly spike glycoprotein stimulated subcloned T lymphocyte target targets TNF-α Vaccine vaccine candidate variants were used [DOI] 10.1371/journal.pone.0268251 PMC 바로가기 [Article Type] Article